In one paragraphArticle in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
5 authors.
Alan N EngelmanDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.ORCID 0000-0002-9709-2591 Duane P GrandgenettDepartment of Molecular Microbiology and Immunology, School of Medicine, Saint Louis University, St. Louis, MO 61304, USA.ORCID 0000-0003-1082-7629 Kristine E YoderDepartment of Cancer Biology and Genetics, The Ohio State University College of Medicine, Columbus, OH 43210, USA.
Mamuka KvaratskheliaDivision of Infectious Disease, Anschutz Medical Campus, University of Colorado, Aurora, CO 80045, USA.
Funding
Nuclear Localization of HIV-1 Preintegration ComplexesR01AI052014 · NIAID · DANA-FARBER CANCER INSTITUTE · PI ENGELMAN, ALAN N. · 2003 to 2025
$11.4MBiochemical Mechanism of HIV DNA IntegrationR37AI039394 · NIAID · DANA-FARBER CANCER INST · PI Alan N. Engelman · 2010 to 2026
$10.2MUltra-potent HIV capsid inhibitorsR01AI157802 · NIAID · UNIVERSITY OF COLORADO DENVER · PI JAMES R FUCHS, Mamuka Kvaratskhelia · 2020 to 2026
$7.1MRoles of HIV-1 capsid-binding FG-motif containing cellular cofactors in infectionR01AI162665 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Mamuka Kvaratskhelia, Gregory B Melikian · 2022 to 2026
$3.9MRole of HIV-1 integrase in virion morphogenesis and its targeting by allosteric integrase inhibitorsR01AI184419 · NIAID · UNIVERSITY OF COLORADO DENVER · PI JAMES R FUCHS, Sebla B. Kutluay · 2024 to 2026
$2.4MVisualization of HIV-1 integration in real timeR01AI150496 · NIAID · OHIO STATE UNIVERSITY · PI KRISTINE E YODER · 2020 to 2026
$2.3MThe Mechanics of Retroviral IntegrationR01AI126742 · NIAID · OHIO STATE UNIVERSITY · PI FISHEL, RICHARD, YODER, KRISTINE E · 2017 to 2021
$1.9MNIAID NIH HHS R01 AI052014NIAID NIH HHS R01 AI126742NIAID NIH HHS R01 AI150496NIAID NIH HHS R01 AI157802NIAID NIH HHS R01 AI162665NIAID NIH HHS R01 AI184419NIAID NIH HHS R37 AI039394
6 · The paper itselfAbstract
The integration of retroviral DNA into host chromosomal DNA is a landmark event that demarcates the transition from the early steps of virus replication to post-integration gene expression and the assembly of new virus particles [...].
Indexed as
RetroviridaeVirus IntegrationAnimalsHumansVirus Replication
Identifiers
PMID40733497
PMCPMC12299400
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390